These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34428715)

  • 1. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.
    Kumar S; Mittal A; Mittal A
    Bioorg Med Chem; 2021 Sep; 46():116354. PubMed ID: 34428715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4).
    Pantaleão SQ; Philot EA; de Oliveira Almeida M; Lima AN; de Sairre MI; Scott AL; Honorio KM
    Curr Top Med Chem; 2020; 20(3):209-226. PubMed ID: 31878857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).
    Shao DW; Zhao LJ; Sun JF
    Eur J Med Chem; 2024 Jun; 272():116464. PubMed ID: 38704940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
    Mohanty IR; Borde M; Kumar C S; Maheshwari U
    Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery approaches targeting the incretin pathway.
    Deng X; Tavallaie MS; Sun R; Wang J; Cai Q; Shen J; Lei S; Fu L; Jiang F
    Bioorg Chem; 2020 Jun; 99():103810. PubMed ID: 32325333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
    Hussain H; Abbas G; Green IR; Ali I
    Expert Opin Ther Pat; 2019 Jul; 29(7):535-553. PubMed ID: 31203700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
    Liu Y; Hu Y; Liu T
    Curr Med Chem; 2012; 19(23):3982-99. PubMed ID: 22709010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based QSAR study to explore the structural requirements of DPP-4 inhibitors: a stepping stone towards better type 2 diabetes mellitus management.
    Dey PK; Dutta R; Ray M; Jakkula P; Banerjee S; Qureshi IA; Gayen S; Amin SA
    SAR QSAR Environ Res; 2024 Jun; 35(6):483-504. PubMed ID: 38904353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
    Sivaraman SA; Sabareesh V
    Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.
    Kuranov SO; Tsypysheva IP; Khvostov MV; Zainullina LF; Borisevich SS; Vakhitova YV; Luzina OA; Salakhutdinov NF
    Bioorg Med Chem; 2018 Aug; 26(15):4402-4409. PubMed ID: 30056037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based lead optimization approach in discovery of selective DPP4 inhibitors.
    Ghate M; Jain SV
    Mini Rev Med Chem; 2013 May; 13(6):888-914. PubMed ID: 23170960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent patents of dipeptidyl peptidase IV inhibitors.
    Mendieta L; Tarrago T; Giralt E
    Expert Opin Ther Pat; 2011 Nov; 21(11):1693-741. PubMed ID: 22017411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
    Singh AK; Jatwa R; Purohit A; Ram H
    J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
    Saglietti G; Placentino G; Schellino A
    Clin Drug Investig; 2014 Jul; 34(7):513-9. PubMed ID: 24788571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.